Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
Princess Margaret Hospital, Canada
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of adenocarcinoma of the prostate within six months of entry
Clinical stage T1B, T1C, T2A-C NX MO (see Appendix 1 for staging). Any Gleason score is eligible for entry, but Gleason score must be determined.
Patients with a PSA \>10.0 and Gleason score of 7; or patients with any PSA value and Gleason score of \>8 must have clinically negative lymph nodes as determined by a pelvic CT scan done within 12 weeks of entry. A negative bone scan is required before entry for all patients with Gleason score \>8, or any patient with a Gleason score of 7, and a PSA \>10.
The patient must not have received any cytotoxic anticancer therapy. Previous or concurrent hormonal therapy for local disease is acceptable.
ECOG performance status of 1 or less
Age 80 years old or less
Serum PSA \<25 ng/ml within 4 weeks of study entry
Informed consent
You may not be if
Patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
Patients with prior colorectal surgery
Any prior pelvic radiotherapy. Any prior TURP done \<12 weeks from study entry.
Any previous cytotoxic chemotherapy
Patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
Clareo Health | Intensity Modulated Radiation Therapy - Prostate Cancer
